Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT05388097 Not yet recruiting - Heart Failure Clinical Trials

Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure

Start date: June 2022
Phase: N/A
Study type: Interventional

The objective of this program is to improve post-acute care coordination for necessary social services for patients leaving the hospital after recovering from an episode of decompensated heart failure.

NCT ID: NCT05388019 Enrolling by invitation - Heart Failure Clinical Trials

Multidisciplinary Ventricular Assist Device Clinic

MultiVAD
Start date: May 2022
Phase: N/A
Study type: Interventional

Current standard of care for ventricular-assist device (VAD) patients is composed of a multidisciplinary team (MDT), which is required in pre-implant and implant hospitalization care but is lacking in post-implant care. Post-implant care is currently centered around the avoidance of complications of VAD support, including cerebrovascular insult (CVA/TIA), gastrointestinal bleeding and infection. Despite major improvements in survival for VAD patients, quality of life and physical functioning measures have not seen significant improvements. This study will include two prospective interventional cohorts and a retrospective control cohort. The first prospective interventional cohort will consist of patients who recently underwent LVAD implantation at Massachusetts General Hospital, and their caregivers. These patients will receive only multidisciplinary team care from the time of their implant. The second prospective interventional cohort will consist of patients who have previously undergone LVAD implantation at Massachusetts General Hospital who are being followed-up with standard-of-care VAD clinic visits, and their caregivers. These patients will receive a hybrid of multidisciplinary team care and standard-of-care visits. The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past and no longer have an LVAD implanted (due to transplant, death, explant, etc.), and will be matched with the prospective interventional patients. The purpose of this study is to characterize the impact of routine MDT care on health-related quality of life, caregiver burnout and functional capacity of outpatient VAD patients, and to determine if implementation of MDT care is associated with a reduction in complications and readmissions in VAD patients at one- and two-years post implant. The investigators hypothesize that the MDT clinic model in addition to standard of care VAD management will positively impact the quality of life and functional status of VAD patients. Subjects who consent to this study will be seen by the MDT providers and complete Cardiopulmonary Exercise Tests (CPET), six-minute-walk-tests, and quality of life questionnaires. The primary caregivers of these subjects will complete a Caregiver Self-Assessment at two timepoints. We anticipate to enroll 20 newly-implanted VAD patients in the pure-MDT arm, 35 pre-existing VAD patients in hybrid-MDT/SOC arm, and 55 primary caregivers.

NCT ID: NCT05387967 Completed - Clinical trials for Heart Failure, Systolic

Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

Start date: January 1, 2021
Phase: Phase 4
Study type: Interventional

This proof-of-concept, open-label non-randomized clinical trial was conducted at a tertiary care cardiac center in Karachi, Pakistan. Patients with HFrEF were prescribed Sacubitril/Valsartan and followed for 12 weeks for the assessment of safety and tolerability. Safety measures included incidence of hypotension, renal dysfunction, hyperkalemia, and angioedema

NCT ID: NCT05384847 Not yet recruiting - Heart Failure Clinical Trials

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

Start date: May 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to determine whether giving triiodothyronine (T3), a thyroid hormone, is safe and helps improve symptoms and signs of heart failure. The study is divided into 2 phases. In the first phase, participants have a 50-50 chance of receiving the study drug. Participants who are randomized to receive the study drug will be admitted to the General Clinical Research Center (GCRC) for 5 days for oral thyroid hormone treatment and monitoring. They will have 4 additional follow-up visits over the next year. Participants who are not randomized to receive the study drug will not be admitted but will have similar follow-up visits in the outpatient setting. Participants who do not receive the drug in Phase 1, will have the opportunity to enroll in Phase 2 of the study where everyone will receive the thyroid hormone treatment. If this study finds that patients have improved heart function after treatment with thyroid hormone without unacceptable side effects, this could result in a new treatment for patients with heart failure.

NCT ID: NCT05383287 Not yet recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction (HFpEF)

Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)

TRAITS-HFpEF
Start date: June 2022
Phase:
Study type: Observational

Heart failure with preserved ejection fraction (HFpEF) accounts for half the number of patients with heart failure, causing significant morbidity and mortality. Unlike heart failure with reduced ejection fraction, there are currently no evidence based treatments that have been shown to improve survival, however there are interventions that have been shown to reduce symptoms by improving exercise intolerance, and prevent hospital admission. Diagnosis can be complex due to the heterogeneity seen in patients presenting with variable symptoms attributed to heart failure. The National Institute for Health and Care Excellence recommends that all patients with suspected heart failure be seen by a clinician with a specialist interest in heart failure. For this reason we are providing a dedicated outpatient service to see patients with suspected or worsening HFpEF, aimed at clarifying clinical diagnosis and providing optimal evidence based treatment and support. This cohort study aims to collect data on this cohort of patients who attend a dedicated outpatient HFpEF clinic. The study aims to provide insights into the epidemiology, co-morbidities, clinical parameters, investigational results including blood tests and cardiac imaging, and the short and long-term prognosis of patients with HFpEF. It will also provide information on the patient population attending a dedicated NHS outpatient HFpEF clinic with the intention to provide information on the functioning of such a service and how this is used to meet patient needs.

NCT ID: NCT05379257 Recruiting - Clinical trials for Congestive Heart Failure

A Feasibility Non-inferiority Clinical Trial for Dosing of Diuretics in CHF Patients

Start date: January 20, 2020
Phase: N/A
Study type: Interventional

Patients with heart failure are frequently hospitalized, have a reduced quality of life and face a higher risk of death. Much of the morbidity and reduced quality of life associated with CHF is related to symptoms of volume overload. Loop diuretics are a mainstay in the management of volume overload and edema in CHF. Diuretic resistance is defined as the clinical state in which diuretic response is diminished or lost before the goal of treatment has been achieved. Diuretic resistance has an adverse effect on clinical outcomes and is associated with a poor prognosis. This open-labeled study will evaluate the option to overcome this resistance in patients with partial of complete loss of the effect via random drug administration using an app. In the present study, the investigators will add the use of a treatment schedule prepared by the physician for each of the patients. This schedule includes a treatment regimen based on the drugs the patient is taking in a pre-determined random change within their approved therapeutic window to be administered by an app. Patients will be followed for 10 weeks and will be compared with their pre-intervention condition. The effect and safety of altering the treatment regimen will be assessed by the need for intravenous diuretics, hospitalizations and emergency department admission and by Kansas City Cardiomyopathy Questionnaire (KCCQ), 6 minutes walk test, creatinine level and pro BNP levels.

NCT ID: NCT05377320 Not yet recruiting - Hypertension Clinical Trials

Patient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity: A Feasibility Study

Start date: June 2022
Phase:
Study type: Observational

This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.

NCT ID: NCT05377190 Not yet recruiting - Heart Failure Clinical Trials

Continuum: Digital Health to Manage Heart Failure Outpatients

Start date: May 2022
Phase: N/A
Study type: Interventional

Heart failure (HF) is one of the leading causes of hospitalization and death worldwide. Remote patient monitoring and digital therapeutics could help reduce the consumption of care for these patients (hospitalizations, emergency room visits) and optimize their management (education, medication optimization). This randomized study aims to evaluate the effects of the Continuum software solution in patients with heart failure, whether or not they are followed in specialized clinics. Heart failure is one of the main causes of hospitalization and death in the world. Evidence suggests that remote patient monitoring (RPM) and digital therapeutics (DTX solutions) can help improve care consumption (i.e. hospitalizations, emergency visits) and also support health care professionals to improve care (i.e. symptoms management, drug optimization). This randomised study aims to evaluate the effects of these two software solutions in the context of specialized HF clinics (HFC) and primary health care on health care consumption and clinical events.

NCT ID: NCT05376748 Recruiting - Atrial Fibrillation Clinical Trials

Exercise Capacity Before and After AF Ablation in Patients With HFpEF

Start date: April 15, 2022
Phase:
Study type: Observational

In a prospective, observational pilot study of patients scheduled for an atrial fibrillation (AF) ablation at the University of Vermont Medical Center the investigators will compare exercise capacity before and four months after AF ablation.

NCT ID: NCT05376254 Recruiting - Heart Failure Clinical Trials

3D Assessment of RV Function in Patients Undergoing LVAD Implantation

Start date: March 22, 2022
Phase:
Study type: Observational

This goal of this study is to analyze images of the right ventricle taken via 3D transesophageal echocardiography (TEE) during left ventricular assist device (LVAD) implantation.